Host genomic HIV restriction factors modulate the response to dendritic cell-based treatment against HIV-1

Alessandra Pontillo, Ronaldo C. Da Silva, Ronald Moura, Sergio Crovella

Research output: Contribution to journalArticlepeer-review


Host genome is still poorly investigated in the context of vaccine or immunotherapy, however recently findings emphasized that it may affect the response to those treatments. In our retrospective study we evaluated the effect of HIV-1 genetic restriction factors on the response to dendritic cell (DC)-based immunotherapy in a Brazilian cohort of HIV positive (HIV+) patients that underwent a phase I clinical trial in 2004. Genomic DNA from 18 HIV+ individuals that underwent DC-based immunotherapy was analyzed for selected polymorphisms known to be associated with susceptibility to HIV-1 infection and/or AIDS progression. Allelic and genotypic distribution of the 22 polymorphisms was evaluated considering the response to the treatment. The rs11884476 SNP in PARD3B resulted associated with good response to the immune treatment according to an over-dominant model. Even if functional effect of this variation is still unknown, our data suggested that it could play a role in the control of viral replication. Our findings, being aware of the limitation represented by the small number of subjects analyzed, suggest that genetic factors involved in AIDS progression could affect the response to immunotherapy, reinforcing the idea that deeper investigation on host genetic variations will be fundamental for a rational vaccine development.

Original languageEnglish
Pages (from-to)512-518
Number of pages7
JournalHuman Vaccines and Immunotherapeutics
Issue number2
Publication statusPublished - 2014


  • DC-based immune-treatment
  • HIV vaccine
  • Host genome and response to vaccine
  • PARD3B

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology
  • Medicine(all)


Dive into the research topics of 'Host genomic HIV restriction factors modulate the response to dendritic cell-based treatment against HIV-1'. Together they form a unique fingerprint.

Cite this